This is a working overview of TB-500, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-18 and is reviewed periodically as new material appears.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
James Upton (1670 in Wilmslow–1749), an English clergyman, schoolmaster and literary editor. Samuel Finney (1719 in Wilmslow–1798), an English miniature painter. William Ewart Gladstone (1809–1898), politician, statesman and Prime Minister four separate times, lived at the Wilmslow Rectory between January and April 1828 to study under the supervision of Reverend John Turner James Tait (1863–1944 in Wilmslow), medieval historian, noted for his retiring, scholarly life in Wilmslow Sir Thomas Barnes (1888–1964), lawyer and HM Procurator General and Treasury Solicitor 1934–1953 Helen Tolson (1888–1955), suffragette, active in the Women's Social and Political Union Alan Turing (1912–1954 in Wilmslow), computer science pioneer and driving force behind the Bombe machine for cracking the German Enigma cypher, is perhaps Wilmslow's most notable resident; he died locally In 2004, a blue plaque was placed on his house in his honour Patrick George (1923 in Wilmslow–2016), an English painter who taught at the Slade School of Fine Art Roger Thatcher (1926–2010), a British statistician, spent his formative early years in Wilmslow Antony Grey (1927 in Wilmslow–2010), pioneer gay rights activist Ronald Brunskill (1929–2015), architectural historian Rod Davies (1930–2015), astronomer and cosmologist, president of the Royal Astronomical Society, and director of Jodrell Bank Observatory Peter Emerson Jones (born 1935), owner of the Emerson Group, a property business lives locally Richard Evans (born 1945 in Wilmslow), a graphic designer, photographer and illustrator Iqbal Ahmed (born 1956), the owner and CEO of the Seamark Group's Asian food business, based in Manchester, lives in Wilmslow John Harris (born 1969 in Wilmslow), a British journalist, writer and critic.
state of the 2028 presidential primaries cycle for the Democratic Party in the upcoming presidential election. August 17 Trump orders the Pentagon to reduce yearly joint exercises with South Korea, saying that the ally refused to help with the 2026 Iran war and citing his good relationship with North Korean leader Kim Jong Un. The 60-day deadline for the US and Iran to negotiate a "final deal" to end the 2026 Iran war expires. Following the official end of the US-Iran ceasefire, Trump urges Iran to surrender. Trump states that the Iranian regime will not agree to the deal that the US feels is needed, and he is not looking to extend the Memorandum of Understanding. Opening statements begin in the murder trial of Duane "Keffe D" Davis, who is accused of orchestrating the 1996 drive-by shooting that killed rapper Tupac Shakur in Las Vegas. August 18 The Defense Department orders an audit of 30 universities' partnerships with foreign institutions, most of which are Chinese, but also include Russian and Iranian institutions. President Tomoko Akane of the International Criminal Court and a senior trial lawyer at the court who was part of a team which sought an arrest warrant for Israeli Prime Minister Benjamin Netanyahu for alleged war crimes in the Gaza war is sanctioned by the US. Newly revealed emails show that a silent channel between ICE and the Iranian government shaped deportation flights in 2025 and 2026 despite tensions mounting between the two states. The national debt surpasses $40 trillion for the first time.
Deuterium, 2H (atomic mass 2.014101777844(15) Da), the other stable hydrogen isotope, has one proton and one neutron in its nucleus, called a deuteron. 2H comprises 26–184 ppm (by population, not mass) of hydrogen on Earth; the lower number tends to be found in hydrogen gas and higher enrichment (150 ppm) is typical of seawater. Deuterium on Earth has been enriched with respect to its initial concentration in the Big Bang and outer Solar System (≈ 27 ppm, atom fraction) and older parts of the Milky Way (≈ 23 ppm). Presumably the differential concentration of deuterium in the inner Solar System is due to the lower volatility of deuterium gas and compounds, enriching deuterium fractions in comets and planets exposed to significant heat from the Sun over billions of years of Solar System evolution. Deuterium is not radioactive, and is not a significant toxicity hazard. Water enriched in 2H is called heavy water. Deuterium and its compounds are used as a non-radioactive label in chemical experiments and in solvents for 1H-nuclear magnetic resonance spectroscopy. Heavy water is used as a neutron moderator and coolant for nuclear reactors. Deuterium is also a potential fuel for commercial nuclear fusion.
Sources: en.wikipedia.org
== External links == Allergies - Americal Academy of Allergy Asthma and Immunology Allergy Blood Testing - Lab Tests Online Radioallergosorbent+Test at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Compared to other TCAs, trimipramine is relatively safe in overdose, although it is more dangerous than the selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) but less dangerous than bupropion in cases of overdose.
The study also found that, in contrast, treatment of transgender women with estrogen and CPA (which is progestogenic in addition to antiandrogenic, unlike NSAAs) resulted in full lobuloalevolar development, as well as pregnancy-like breast hyperplasia in two of the subjects. In addition, it was observed that the lobuloalveolar maturation reversed upon discontinuation of CPA after sex reassignment surgery in these individuals. It was concluded that progestogen in addition to antiandrogen/estrogen treatment is required for the induction of full female histological breast development (i.e., that includes complete lobuloalveolar maturation), and that continued progestogen treatment is necessary to maintain such maturation. It should be noted however that although these findings may have important implications in the contexts of lactation and breastfeeding, epithelial tissue accounts for approximately only 10% of breast volume (with the bulk of the breasts (80–90%) being represented by stromal or adipose tissue), and it is uncertain to what extent, if any, that development of lobuloalveolar structures (a form of epithelial tissue) contributes to breast size and/or shape.
However, general purpose computer programs that are used to derive equilibrium constant values from experimental data use association constants for both acids and bases. Because stability constants for a metal-ligand complex are always specified as association constants, ligand protonation must also be specified as an association reaction. The definitions show that the value of an acid dissociation constant is the reciprocal of the value of the corresponding association constant:
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.